Tuesday, 21 January 2020

Plasma Fractionation Market Statistics 2019 by Key Driving Factor, Dazzling Growth, Vital Players, Regions, Segments, Diagnosis, Treatment & End-User Outlook to 2023

Plasma Fractionation Market Research Report: By Product (Immunoglobulin, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, and Others), Application (Immunology, Neurology, Hematology, and Others), End User – Global Forecast Till 2023
Plasma Fractionation Market Scenario:
Increasing prevalence of immunodeficiency disorders and rising healthcare expenditure are also boosting the plasma fractionation market in the US region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
Rising participation of market players is one of the key factors driving the plasma fractionation market. For instance, in 2018, Grifols acquired 24 plasma donation centers in the United States operated by Biotest Pharmaceuticals Corp. for USD 286 million. With this acquisition, Grifols now owns 249 plasma donation centres to increase its supply of plasma proteins used for therapeutic purposes.
In plasma fractionation process protein products are fractionated from human plasma for the prevention, and treatment of life-threatening conditions such as congenital deficiencies, immunologic disorders, and others.
Global Plasma Fractionation Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 18073 million in 2017 and is projected to grow at a CAGR of 6.5% over the forecast period.
Various other factors such as increasing geriatric population, technological advancements, emerging markets in APAC and RoW, rising plasma collection, and increasing prevalence of respiratory and autoimmune disorders are also expected to propel the growth of the market.
However, the emergence of recombinant alternatives, high cost of advanced products, and unfavourable reimbursement policies can hamper the market growth over the forecast period.
Segmentation
The global plasma fractionation market is segmented based on product, application, end user, and region.
The global market for plasma fractionation, by product is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment is further classified as intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and others. The coagulation factor concentrates segment is further classified as Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, and Factor XIII.
Based on application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others.
Based on end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The plasma fractionation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European plasma fractionation market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The plasma fractionation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The plasma fractionation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for plasma fractionation owing to the presence of major market players and increasing prevalence of immunodeficiency disorders within the region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
In 2017, it was estimated that Europe stood second in the global plasma fractionation market. This can be attributed to the increasing technological advancements, and rising R&D investments.
Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure drives the regional markets of the Asia Pacific region. According to the Australian Institute of Health and Welfare, from 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health.
On the other hand, the Middle East and Africa held least share in the global plasma fractionation market due to inadequate economic development, especially within the African region.
Browse More Healthcare Reports @
Posted by at No comments:
Labels:

Atherectomy Devices Market Size, Share, Development, Growth and Demand Forecast to 2023

Atherectomy Devices Market Research Report, by Product Type (Directional Atherectomy Systems, Orbital Atherectomy Systems, and others), by Application (Cardiovascular, Neurovascular, Peripheral Vascular, and others), by End User–Forecast Till 2023
Market Scenario
Atherectomy devices are built to either shave, cut, vaporize, laser or sand the plaques. The devices come with different indications. Different atherectomy devices have been invented for commercial use. The location of the plaque and type of blockage influence the choice of atherectomy device to be used. Some atherectomy devices are used only in the larger arteries on the upper portion of the knee, while other devices come with smaller catheters that are suitable for operating the arteries below the knee.
Atherectomy is a technique applied to eliminate atherosclerotic plaque from affected arteries. The plaques are in either peripheral or coronary arterial vasculature and may have distinct characteristics depending on the nature of the plaque. Atherectomy is used widely in cure of both peripheral and coronary arterial ailments. It is a minimally invasive endovascular surgery.
The worldwide Atherectomy devices market is likely to develop remarkably over the forecast period. It is projected that the global atherectomy devices market will register a CAGR of 6.12% over the forecast period of 2018–2023. In 2017, the estimated market value was around 1.09 billion.
The growing rate of peripheral and coronary arterial diseases coupled with increasing demand for minimally invasive techniques is predicted to boost the growth of the atherectomy devices market. Minimally invasive surgical techniques deliver quicker recovery, quick procedural time, lesser risk of infections and complications. The worldwide atherectomy devices market is likely to witness noteable surge in demand due to exponential growth in the incidence of lifestyle-related ailments and elderly population.
Segmentation
The global atherectomy devices market is segmented on the basis of product type, application, and end user.
Based on application, the atherectomy devices market is segmented into cardiovascular, neurovascular, peripheral vascular, and others.
The atherectomy devices market, by product type is categorised into directional atherectomy systems, orbital atherectomy systems, photo-ablative (laser) atherectomy systems, rotational atherectomy systems, and others.
The directional atherectomy systems segment is expected to hold the largest share owing to the high treatment rate, whereas the photo-ablative (laser) atherectomy systems is expected to be the fastest growing segment owing to the growing preference by surgeons.
On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, and others.
On the basis of region, the global atherectomy devices market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The atherectomy devices market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Asia-Pacific was projected to be the fastest growing region for the global atherectomy devices market. This owes to the technological advancements resulting in the development of cost-effective atherectomy devices leading to high acceptance rate for the devices in the Asia-Pacific region. The Middle East and Africa holds the least share in the global atherectomy devices market due to the presence of economically diverse countries, and less initiatives taken by the government.
It is projected that the Americas dominated the global atherectomy devices market owing to the growth of the market in the North American region. This is largely attributed to the factors such as increase in research funding, and growing awareness about the high-end atherectomy devices among medical professionals. Europe is expected to hold the second largest share in the atherectomy devices market owing to growing healthcare infrastructure. Additionally, various initiatives by public and private organizations is anticipated to boost the growth of the atherectomy devices market.
Browse More Healthcare Reports @
Posted by at No comments:

Dental Bone Graft Substitutes Market Rapidly Growing in Healthcare, Competitor Analysis, Complete Study of Current Trends and Forecast 2019-2023

Dental Bone Graft Substitutes Research Report: by Type (Allograft, Xenograft, Alloplast), by Application (Ridge Augmentation, Sinus Lift, Socket Preservation, Periodontal Defect), by End User (Dental Clinics and Hospitals) - Global Forecast Till 2023
Market Scenario:
The increasing incidence of oral diseases such as, dental caries and periodontal diseases, growing ageing population, and growing medical tourism in developing countries are expected to drive the growth of market. Dental tourism is increasing because dental patients mostly from a developed country are getting attracted towards other developing countries. Dental patients prefer to travel to the countries because these countries are providing cost effective and high-quality treatment. Mostly, the treatments in the dental tourism centers around the demand for dental implants. Countries like Hungary, India, South Korea and Turkey are increasingly gaining popularity in the area of dental tourism for their low cost and effective oral health treatment. On other hand, lack of proper reimbursement and stringent regulations can restrain the market growth over the assessment period. Moreover, increasing burden of oral diseases drive the growth of the market. According to Centers for Disease Control and Prevention (CDC), about 64.7 million Americans were suffered with periodontal disease.
Global dental bone graft substitutes market is expected to grow significantly over the forecast period. It is anticipated that the market held value of USD 461.3 million in 2017 and is projected to grow at a CAGR of 9.4% over the forecast period.
Global Dental Bone Graft Substitutes, by Key Players
  • Biohorizons Iph, Inc. (US)
  • Geistlich Pharma AG (Switzerland)
  • Dentsply Sirona (US)
  • Institut Straumann AG (Switzerland)
  • Medtronic Plc (US)
  • Zimmer Biomet Dental (US)
  • Dentium (South Korea)
  • LifeNet Health (US)
  • Orthogen, LLC (US)
Segmentation
The global dental bone graft substitutes market has been segmented into type, application, and end user.
Based on type, dental bone graft substitutes market is segmented into allograft, xenograft, alloplast, and others.
Based on application, dental bone graft substitutes market is segmented into ridge augmentation, sinus lift, socket preservation, periodontal defect, and implant bone regeneration.
Based on end user, dental bone graft substitutes market is segmented into dental clinics, hospitals, and others. The dental clinics segment is expected to account for the largest share segment of the market in 2017.
The dental bone graft substitutes market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The dental bone graft substitutes market in the Americas further segmented into North America and South America, with the North American market divided into the US and Canada.
The European dental bone graft substitutes market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The dental bone graft substitutes market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The dental bone graft substitutes market in the Middle East & Africa segmented into the Middle East and Africa.
Regional Summary
Geographically, the Europe is expected to dominate the global dental bone graft substitutes market owing to the presence of well-established players, increasing incidence of oral diseases namely, dental caries and periodontal diseases, and growing ageing population. The Americas is expected to hold the second largest position in the global dental bone graft substitutes market. Asia-Pacific is expected to be the fastest growing market owing to growing medical tourism in developing countries and growing ageing population. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global dental bone graft substitutes market.
Browse More Healthcare Reports @
Posted by at No comments:

Anti-Hypertensive Drugs Market: 2019 Global Size, Trends, Investments, Share, Leading Players, Merger, Acquisition, Growth Factors, Regional Analysis, And Industry Forecast To 2023

Antihypertensive Drugs Market Research Report: by Therapeutic Class (Calcium Channel Blockers, Beta-adrenergic Blockers, Renin Inhibitors, ACE Inhibitors, Vasodilators, Diuretics, ARBs, Others), by Type (Primary Hypertension, Secondary Hypertension), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores, Others), and Region - Global Forecast till 2023
According to a recent study report published by the Market Research Future, The global market of  Anti-Hypertensive Drugs was valued at $32.2 billion in 2015, and is projected to reach $ USD 41.2 billion by 2023. Thus the anti-hypertensive drugs market is anticipated to observe a sluggish growth; at a CAGR of 2.73% during 2016 to 2022.
Anti-Hypertensive Drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults. Hypertension is one of the most powerful risk factors for cardiovascular morbidity and mortality. There exact cause of hypertension is unknown but is said that unhealthy, heady lifestyle and ageing mirror such disorders as “Hypertension”.
The major market driving factors for secondary hypertension are greater detection and early diagnosis. Rise in the prevalence diseases such as kidney problems, thyroid problems, adrenal gland tumours, heart ailments, chronic alcohol use etc. in which anti-hypertensive drugs are used; are some of the other factors driving the growth of the Anti-Hypertensive Drugs market. The constraints however are overwhelming and include patent expiries such as Actelion's Tracleer (2015), and United Therapeutic's Remodulin (2014). Other blockbuster’s such as Novartis's Diovan and Exforge, Sanofi Aventis's Avapro (2012) etc are also off-patent.
Many antihypertensive drugs have their primary action on systemic vascular resistance. Some of these drugs produce vasodilation by interfering with sympathetic adrenergic vascular tone (sympatholytics) or by blocking the formation of angiotensin II or its vascular receptors. Other drugs are direct arterial dilators, and some are mixed arterial and venous dilators. Although less commonly used because of a high incidence of side effects, there are drugs that act on regions in the brain that control sympathetic autonomic outflow. By reducing sympathetic efferent activity, centrally acting drugs decrease arterial pressure by decreasing systemic vascular resistance and cardiac output.
Some antihypertensive drugs, most notably beta-blockers, depress heart rate and contractility (this decreases stroke volume) by blocking the influence of sympathetic nerves on the heart. Calcium-channel blockers, especially those that are more cardioselective, also reduce cardiac output by decreasing heart rate and contractility. Some calcium-channel blockers (most notably the dihydropyridines) are more selective for the systemic vasculature and therefore reduce systemic vascular resistance.
Segmentation
The Anti-Hypertensive Market can be segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;
Segmentation By Pharmacological Class            : Comprises Diuretics, ACE Inhibitors, Calcium Channel Blockers, Adrenergic Blocker and other.
Segmentation By Hypertension Type                 : Comprises Systemic and Pulmonary Hypertension Drugs and other.
Segmentation By Disease Source                      : Comprises Primary and Secondary.
Segmentation By Regions                                : Comprises Geographical regions - North America, Europe, APAC and Rest of the World.
Regional Analysis
The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.
The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.
The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.
Key Players
Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. are some of the prominent players at the forefront of competition in the Global Market of Anti-Hypertensive Drugs and are profiled in MRFR Analysis.
Posted by at No comments:

Handheld Surgical Devices Market Growth Trends, Size Estimation, Industry Analysis, Sales Statistics, Global Share, Leading Key Players and Regional Forecast 2023

Handheld Surgical Devices Market Research Report: By Application (Neurology, Orthopaedics, Cardiovascular, Urology, others), Product (Auxiliary Devices, Cutter Devices, Dilators, Forceps and Spatulas, & Others), End User – Global Forecast Till 2023
Market Scenario:
Increasing number of surgical procedures is the key factor driving the handheld surgical devices market. According to the Australian Institute of Health and Welfare, during 2015–16, there were 10.6 million hospitalisations, and 1 in 4 hospitalisations involved a surgical procedure.
The Global handheld surgical devices market is expected to grow at an approximate CAGR of 6.8% during forecast period, 2019–2023.
The handheld surgical devices are specially designed for specific surgeries. These are available in a wide variety of shapes and sizes.
Various other factors such as increasing incidence of accidents, high geriatric population, technological advancements, increasing demand for plastic & reconstructive surgery, and rising patient awareness regarding the benefits of handheld surgical devices are also expected to propel the growth of the market.
Key players
Some of the key players in the global handheld surgical devices market are B. Braun Melsungen AG, Integra LifeSciences Corporation, Zimmer Biomet Holdings, Pelion Surgical, Medtronic, Smith & Nephew, Johnson & Johnson, Millennium Surgical Corp, Medicon Eg, Elite Medical, Becton, Dickinson and Company (BD), Thompson Surgical, Stryker, Aspen Surgical, KLS Martin, CooperSurgical Inc., and others.
Segmentation
The global handheld surgical devices market is segmented based on application, product, end user and region.
The global market for handheld surgical devices, by application is segmented into neurology, urology, orthopedics, gynecology, cardiovascular, wound closure, and others.
The market, by product, is segmented into forceps and spatulas, retractors, dilators, graspers, auxiliary devices, cutter devices, and others. The auxiliary devices segment is further classified as clamps, cannulas, and closure devices. The cutter devices segment is further classified as trocars, lancets, and scissor. The others segment includes punches, curettes, blunt dissectors, and snares.
Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centres, research and academic institutes, and others. Clinics held a lucrative market share in 2017 due to rising prevalence of chronic conditions.
Regional Analysis
The Americas dominated the global market for handheld surgical devices owing to the increasing prevalence of chronic conditions, and high geriatric population.
In 2017, it was estimated that Europe stood second in the global handheld surgical devices market. This can be attributed to the increasing cases of surgical procedures, and rising research and development investments. According to the 2016 data suggested by Eurostat, around 1040.8 cases of cataract surgery and 406.2 cases of transluminal coronary angioplasty are registered in Germany.
Asia Pacific was projected to be the fastest growing region in 2017. Factors such as growing healthcare sector, increasing penetration of the market players within the region, increasing healthcare expenditure, a rising number of surgical procedures drive the regional markets of the Asia Pacific region. On the other hand, the Middle East and Africa held least share in the global handheld surgical devices market due to the low per capita income, especially within the African region.
Browse More Healthcare Reports @
Posted by at No comments:
Labels:

Global Cerebrospinal Fluid Management Devices Market to Quadruple by 2023; Foretells MRFR

Cerebrospinal Fluid Management (CSF) Devices Market Research Report: By Product (Shunts, Valve, External Drainage System), Age Group (Paediatric, Adult, Geriatric), End User (Hospitals, Ambulatory Settings, and others) – Global Forecast Till 2023
Market scenario
Rising cases of hydrocephalus is one of the key factors driving the cerebrospinal fluid management (CSF) devices market. According to the Brain Foundation, one in every 1,000 Australian children is born with hydrocephalus annually.
Global cerebrospinal fluid management (CSF) devices market is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 4.5% over the forecast period.
Various other factors such as rising research & development expenditure, geriatric population, technological advancements, growing adoption of minimally invasive procedures, and rising awareness about hydrocephalus are also expected to propel the growth of the market.
However, lack of trained professionals, side-effects associated with the treatment, and high cost of devices can hinder the market growth over the forecast period.
Key players
Medtronic plc, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, DePuy Synthes, Spiegelberg GmbH & Co. KG, SOPHYSA, Natus Medical Incorporated, Dispomedica GmbH, Delta Surgical Limited, Argi Grup, Moller Medical GmbH, G. SURGIWEAR LTD., Wellong Instruments Co., Ltd., BeckerSmith Medical, Inc., and others.
Segmentation
The Global cerebrospinal fluid management (CSF) devices market is segmented based on product, age group, end user, and region.
The Global market for cerebrospinal fluid management (CSF) devices, by product is segmented into shunts, valve, and external drainage systems.
The shunts segment is further classified as ventriculoperitoneal (VP), ventriculoatrial (VA), lumboperitoneal (LP), and ventriculopleural (VPL). The valve segment is further classified as fixed, and adjustable. The external drainage systems segment is further classified as external ventricular drainage (EVD) systems, and lumbar drainage (LD) systems.
Based on age group, the market is segmented into paediatric, adult, and geriatric.
Based on end user, the market is segmented into hospitals, ambulatory settings, clinics, research and academic institutes, and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The cerebrospinal fluid management (CSF) devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European cerebrospinal fluid management (CSF) devices market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cerebrospinal fluid management (CSF) devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cerebrospinal fluid management (CSF) devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for cerebrospinal fluid management (CSF) devices owing to the rising geriatric population and presence of major market players. As per the 2018 statistics suggested by the U.S. Census Bureau, by 2035, there will be 78 million people 65 years and older compared to 76 million under the age of 18.
In 2017, it was estimated that Europe stood second in the global cerebrospinal fluid management (CSF) devices market. This can be attributed to the rising research and development investments and increasing technological advancements.
Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure and rising cases of hydrocephalus drives the regional markets of the Asia Pacific region. According to the Hydrocephalus association, approximately 200,000 cases of congenital hydrocephalus in infants are registered around the world. However, in India, nearly 12,000 cases of congenital hydrocephalus are registered each year.
On the other hand, the Middle East and Africa held least share in the global cerebrospinal fluid management (CSF) devices market due to the low per capita income and stringent government policies, especially within the African region.
Browse More Healthcare Reports @
Posted by at No comments:
Labels:

Amyotrophic Lateral Sclerosis Market Rapidly Growing in Healthcare, Competitor Analysis, Complete Study of Current Trends and Forecast 2019-2023

Market Scenario
The Global ALS market valuation is expected to surpass USD 841.6 million by 2023, growing at approximately 7.89 % CAGR over the forecast period (2019-2023). In 2017, the market had a valuation of USD 526 million. Market Research Future presents report by By Type (Familial ALS), by Treatment (Medication, Physical Therapy, Speech Therapy), by Diagnosis (Laboratory Tests, Imaging Tests), End-User (Hospitals, Specialty Centers) and Global forecast till 2023
ALS or Amyotrophic Lateral Sclerosis is a neurological ailment which affects the nerve cells in the spinal cord and the brain that controls the voluntary muscles’ activities. Some of the common symptoms of ALS include cramps, muscle weakness, respiratory problems, and fasciculation. This is a progressive neurological disease where gradually patients become dependent on physicians and caregivers increasingly. Often ALS results in respiratory failure as the patient loses the ability of controlling the muscles both in the diaphragm and the chest. Ultimately, it turns fatal.
Additional factors such as the inclination towards the sedentary lifestyle are driving the market growth and increasing the risk of developing ALS. Besides, the increasing geriatric population substantiates market growth, creating a demand for symptomatic and targeted treatment options.
But the high cost of the treatment of ALS may hinder the market growth over the forecast period.
Segments                                                                                                                                            
The Global amyotrophic lateral sclerosis market has been segmented on the basis of type, treatment, and end-user.
By type, the market is segmented into sporadic and familial ALS. The sporadic ALS, also abbreviated as SALS, was the largest segment in 2017 and can dominate the market over the forecast period.
By treatment, the amyotrophic lateral sclerosis market has been segmented into medication, physical therapy, respiratory therapy, speech therapy, and others. Out of these, medication had the largest market in 2017.
By end-user, the ALS market has been segmented into hospitals, specialty centers, research & academic institutes, and others. Among these, the subsegment Hospital accounts for the largest segment.
Regional Analysis
By Regions, the global amyotrophic lateral sclerosis market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is estimated to dominate the global ALS market owing to the increasing pool of awareness and the rising prevalence of hypertension. ALS remains a significant public health challenge in the US. Therefore, governments and private non-profit organizations are developing specific guidelines for the management and treatment of ALS. Public and private organizations are involved in strategic partnerships and collaborations in search for a better outcome in the research of amyotrophic lateral sclerosis treatment in the region.
The amyotrophic lateral sclerosis market in the European region stands at the second position in terms of the market size mainly due to the well-established healthcare sector. Several companies and research institutes are also establishing advanced facilities to research ALS.
Moreover, in recent years, there has been an increase in the adoption of sedentary lifestyles among people. Research shows that an increase in physical activities such as exercise helps in reducing the pain and thwarting some of the symptoms such as loss of motion in patients who have ALS.
Thus, the inclination towards the sedentary lifestyle increases the risk of developing ALS among the elderly population, thus creating a demand for symptomatic and targeted treatment options. The development of novel therapeutic approaches and advanced treatment options are likely to push the growth of the amyotrophic lateral sclerosis market during the forecast period.
Whereas, the ALS market in the Asia Pacific region is expected to grow rapidly due to the increasing prevalence of the disease and rapidly developing healthcare infrastructure. The increasing economy in the region is playing a vital role in the growth of the market. Furthermore, the increase in the setups of research and development centers also fuels the growth of the ALS market in the region.
Key Players                                                                                                         
  • Sun Pharmaceutical (India),
  • Mitsubishi Tanabe Pharma America (U.S.),
  • Biogen (U.S.),
  • Sanofi (France),
  • Mylan N.V. (U.S.),
  • Covis Pharma (Switzerland),
  • Ionis Pharmaceutical (U.S.),
  • ITF Pharma (U.S.),
  • Ascend Pharmaceuticals LLC (U.S.),
  • Apotex Inc. (Canada).
Feb 2019- Leading technology transfer company, BGN Technologies has lately disclosed about a new AI (artificial intelligence) platform to monitor and predict the development of neurodegenerative diseases in order to identify markers both for improved drug development and personalized patient care. This technology will focus on ALS at an initial stage and later on will be adapted to other neurodegenerative diseases namely Alzheimer’s and Parkinson’s. The latest technology will predict disease progression more accurately, a key component for clinical trials along with better identifying the interrelationships amid demographics and many other measurable factors that are identified through patient functionality and physical examinations. It will allow researchers in creating a system which insurers, HMOs, pharmaceutical companies, caregivers, physicians, and patients can use on mobile applications and desktop for monitoring and predicting ALS progression.
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)